Media headlines about Crispr Therapeutics (NASDAQ:CRSP) have been trending somewhat positive on Thursday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Crispr Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the company an impact score of 43.6541521776651 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 (finance.yahoo.com)
- [$$] Celgene: Two Small-Cap Biotech Stocks It’s Selling (finance.yahoo.com)
- Brokerages Expect Crispr Therapeutics AG (CRSP) to Announce -$0.74 Earnings Per Share (americanbankingnews.com)
- Moving averages give many trading signals on CRISPR Therapeutics AG (CRSP) – Wall Street Morning (wallstreetmorning.com)
- Crispr Therapeutics Target of Unusually Large Options Trading (CRSP) (americanbankingnews.com)
A number of equities analysts have issued reports on the stock. Oppenheimer reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. SunTrust Banks reaffirmed a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research note on Friday, November 10th. Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Barclays reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a research note on Friday, September 8th. Finally, Piper Jaffray Companies assumed coverage on shares of Crispr Therapeutics in a research note on Friday, December 22nd. They issued an “overweight” rating on the stock. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Crispr Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $22.38.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The company’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter last year, the business posted ($2.77) earnings per share. equities research analysts expect that Crispr Therapeutics will post -2.46 EPS for the current fiscal year.
In related news, Director Thomas Woiwode sold 1,700 shares of the firm’s stock in a transaction on Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the sale, the director now directly owns 8,218 shares in the company, valued at $166,085.78. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Tyler Dylan-Hyde sold 15,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $18.90, for a total transaction of $283,500.00. Following the sale, the insider now owns 130,204 shares in the company, valued at $2,460,855.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,950,654 shares of company stock worth $37,126,688. Company insiders own 39.98% of the company’s stock.
WARNING: “Crispr Therapeutics (CRSP) Earning Somewhat Positive Press Coverage, Report Shows” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/28/crispr-therapeutics-crsp-earning-somewhat-positive-press-coverage-report-shows.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
What are top analysts saying about Crispr Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Crispr Therapeutics and related companies.